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The objective of non-inferiority trials is to demonstrate the efficiency of a novel treatment 
whether it is acceptably less or more efficient than a control or active (existing) treatment. 
They are employed in situations where, when compared to the active treatment, the novel 
treatment is to be advantageous with higher rates of reliability, compatibility, cost-
efficiency, etc. Odds ratio is the most significant measure used in investigating the size of 
efficiency of treatments relative to one another. The purpose of the study is to calculate 
and evaluate the sample size under different scenarios based on three different test statistics 
in non-inferiority trials for one proportion via Monte Carlo simulations. 
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Introduction 
In clinical trials, the aim is to display whether the use of a novel drug or a novel 
medical instrument will be efficient and reliable. It is a widespread practice that a 
treatment is compared with a control group or a placebo group. One such practice 
is the employment of non-inferiority trials. Non-inferiority trials involve testing the 
effectiveness of a novel treatment that is acceptably less/more effective than a 
control or active (existing) treatment. They are performed in situations where 
compared to the active (existing) treatment, the novel treatment is to be 
advantageous with higher rates of reliability, compatibility, cost-efficiency, etc. In 
order to ensure reliability, these trials should be designed in accordance with correct 
statistical methods. A proper scientific study needs to follow certain steps, such as 
formulating hypotheses, applying the appropriate test statistic, determining the 
sample size, collecting the data, analyzing the data, and finally interpreting the data. 
Sample size is one of the most important factors that impact the reliability and 
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correctness of a clinical trial. It plays an essential role in ensuring the validity, 
correctness, reliability, and integrity of the targeted clinical trial (Chow, Shao, & 
Wang, 2008). 
Power analysis is the most frequently applied method used to calculate the 
sample size. Power analysis refers to the calculation of the required sample size that 
can yield the clinically/statistically significant difference and thus provide the 
expected power under conditions where Type-I error is invariant. A designed 
clinical trial is expected to have adequate power at an appropriate significance level. 
Generally, the power value is expected to be over 80%. If the power of the 
employed test is low, that test may fail to detect a difference that really exists 
(Schlotzhauer, 2007; Alkan, Terzi, & Alkan, 2015). There are many studies within 
the literature regarding the calculation of the adequate sample size (Alkan et al., 
2015; Desu & Raghavarao, 1990; Julious, Campbell, & Altman, 1999; Machin, 
Campbell, Tan, & Tan, 2009; Tekindal & Yazıcı, 2016; Demirel, Oruç, & Gürler, 
2016). 
Hahn (2012) noted sample size is highly sensitive with respect to the expected 
effects within treatment and control groups. A much larger sample size is needed 
in order to analyze the situations where the novel treatment is much less effective 
than the control group, whereas a smaller sample size is sufficient in case the novel 
treatment is a bit more effective than the control group. As the non-inferiority 
margin increases, the required sample size decreases. On the other hand, it was also 
concluded that the exaggeration of this ratio reduces the power of the test. 
Walker and Nowacki (2010) reported the non-inferiority margin is directly 
influential on the sample size. They produced different sample sizes with non-
inferiority margins ranging from 0.06 to 0.12 with values increasing at 0.01 units. 
When the power of the test was 80% and the non-inferiority margin was set as 0.06, 
the required sample size was calculated as 26,186, whereas the required sample size 
decreased to 535 with 0.12 non-inferiority margin under the same conditions. In 
conclusion, they demonstrated that small changes in non-inferiority margin may 
lead to bigger changes in the sample size. 
Assuming α = 0.05 and baseline proportion as 0.5, Tunes-da-Silva (2008) 
calculated the required sample size to reach the power of test at 80% and 90%. As 
the non-inferiority margin decreased, the sample size to meet the target power of 
both tests increased. In addition, they analyzed the relationship between non-
inferiority odds ratio and baseline proportion, and found as the baseline proportion 
changes, non-inferiority odds ratio changes as well. In this respect, they emphasized 
that the necessity of using the appropriate proportion specified by the clinicians. 
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The objective of this study is to calculate and assess the proper sample size 
for a sample rate at non-inferiority trials via three different test statistics (exact test, 
Z test, and Z-test with continuity correction) under different scenarios. 
Methodology 
The Type-I error was set at 0.05; baseline proportion was 0.50; and different non-
inferiority odds ratios (0.75, 0.80, 0.85, 0.90, 0.95, 0.99) were considered. POdds 
was calculated for odds ratios 0.1875, 0.2, 0.2125, 0.225, 0.2375, and 0.2475. The 
data were derived from a binomial distribution (p = 0.5) with different non-
inferiority odds ratios (0.75, 0.80, 0.85, 0.90, 0.95, 0.99) via increasing the sample 
size from 10 to 500 by 1 to calculate the power of the test. Having rendered 10000 
repetitions for each scenario via Monte Carlo simulation method, the results were 
further evaluated. The power of the test calculated via using PASS Version 11 
(Hintze, 2011). 
Non-Inferiority Trials 
In clinical trials, the dual character displaying response variable is commonly used 
in particular for testing the effectiveness of a drug or a medical instrument, or for 
comparing the treatment groups. In classical hypothesis testing, the ratios obtained 
from the novel and the active (existing) treatment groups are compared to see if 
there is a statistically or clinically significant difference. Nevertheless, the 
researchers may want to prefer the novel treatment to the active (existing) treatment 
only under the conditions where the former being less costly and having less 
adverse effects. Likewise, in certain studies, the use of placebo may not be ethical. 
Hence, a need to detect whether the novel treatment is either equal or non-inferior 
to the existing treatment emerges. These studies are referred as non-
inferiority/equivalence studies and their analyses require simple modifications 
within the classical hypotheses. For instance, assume that the success rate of an 
existing treatment on a certain disease is 70%. However, this treatment is expensive, 
and sometimes displays serious adverse effects. Therefore, the researchers have 
developed a novel treatment, and it is ready for testing. One of the leading questions 
to be answered is whether the new treatment will be as good as the existing one. In 
other words, will at least 70% of the treated subjects positively respond to the novel 
treatment? The novel treatment may be chosen even if it is less effective than the 
existing one. In this case, there is a need to determine to what extent the novel 
treatment can be less effective. Determined by the researchers, this value is called 
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the non-inferiority margin. The determination of the non-inferiority margin, δ, is 
the most critical step in equivalence/non-inferiority testing. 
Being the maximum acceptable extent of clinical non-inferiority of an 
experimental treatment, the non-inferiority margin δ must be prospectively defined. 
One approach to specifying the margin is based on clinical significance, which can 
obviously be subjective. Sometimes it is possible to choose a margin for declaring 
non-inferiority of a treatment, in which that treatment ends up having no effect or 
even a detrimental effect (Hahn, 2012). 
The International Conference on Harmonisation (ICH) documents offer two 
guidelines (ICH, 2000; D’Agostino, Massora, & Sullivan, 2003): 
 
1) The determination of the margin in a non-inferiority trial is based on 
both statistical reasoning and clinical judgement, and should reflect 
uncertainties in the evidence on which the choice is based, and should 
be suitably conservative. 
2) This non-inferiority margin cannot be greater than the smallest effect 
size that the active drug would be reliably expected to have compared 
with placebo in the setting of a placebo-controlled trial. 
Testing for Non-Inferiority using Odds Ratio 
Let P represent the proportion responding as a success. That is to say, P is the actual 
probability of a success in a binomial experiment. In a non-inferiority experiment, 
the baseline proportion is the response rate of the active treatment. Furthermore, P0 
represents the response proportion that is tested in the null hypothesis, H0. 
Non-inferiority trials are the studies showing that the novel treatment is 
clinically less different/effective than the existing treatment. Let PN represent the 
smallest value of P that still results in the conclusion that the novel treatment is 
non-inferior to the current treatment. The relevant hypothesis equation is given in 
(1): 
 
 0 1H : vs H :P PN P PN    (1) 
 
For the analysis of the non-inferiority trials, three different methods, namely 
difference, ratio, and odds ratio (OR), are applied. In this study, OR, which is the 
most frequently used method to reveal the effectiveness of two treatment methods, 
is employed (Wang & Chow, 2007). 
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The odds of an event are calculated by dividing the event risk by the non-
event risk. Thus the odds ratio for P1 and P0 is defined as 
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In practice, the log-scaled odds ratio is defined as θ = log(OR). An estimator of θ 
can be obtained as 
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Testing the non-inferiority hypotheses for the odds ratio, 
 
 0 1H : vs H :       (4) 
 
where δ is the noninferiority or superiority margin on the log-scale. Define the 
following test statistic 
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For a given significance level α, the null hypothesis would be rejected if T > zα. On 
the other hand, under the alternative hypothesis, the power of the above test can be 
approximated by 
 
 ( )
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  (6) 
Power and Sample Size Non-Inferiority Using Odds Ratio 
Power refers to the probability of establishing the true research hypothesis. Power 
analysis can also be defined as the calculation of the necessary sample size to 
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achieve the targeted power. Selection of the adequate sample size depends on the 
clinically significant difference, the targeted power, the pre-defined significance 
level, and the relevant hypotheses within the scope of the study. Besides, the non-
inferiority margin is also a directly influential factor on the sample size in non-
inferiority trials. The calculation of adequate sample size regarding non-inferiority 
using odds ratio is given in equations (7) and (8) (Wang & Chow, 2007). 
Power 
The sample size needed for achieving the power of 1 − β can be obtained by solving 
the following equation 
 
 ( )
( ) ( )
1 2
2
1 1 1 0 0 0
1 1
1 1
z z
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−
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Sample Size 
Assuming that n1 / n0 = K, 
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  (8) 
Results 
Assuming that Type-I error is 0.05 and baseline proportion is 0.50, data were 
produced with different non-inferiority odds ratios (0.75, 0.80, 0.85, 0.90, 0.95, 
0.99) at different sample sizes from 10 to 500. The cases when the power of the test 
reach 80% while non-inferiority odds ratio is 0.75 are displayed in Tables 1-3 and 
Figures 1-3. 
Table 1 and Figure 1 indicate that the power of the test exceeds 80% only 
when the non-inferiority odds ratio is 0.75. The power of the test decreases in other 
proportions. Table 2 and Figure 2 display that the power of the test reaches and 
exceeds 80% when the non-inferiority odds ratios are 0.75 and 0.80. The power of 
the test decreases in other proportions. Table 3 and Figure 3 show that the power 
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of the test happens and exceeds 80% only when the non-inferiority odds ratios are 
0.75 and 0.80. The power of the test decreased in other proportions. 
Conclusions 
Novel treatments are developed due to technological advances in medicine. Even 
though they have similar or less effectiveness compared to the active (existing) 
treatments, the novel treatments are preferred as long as they provide more benefits. 
In some occasions, the active (existing) treatment may be costlier or having severe 
adverse effects. Furthermore, the use of placebo may not be ethical or the active 
(existing) treatment may be controversial. In such cases, non-inferiority tests are 
frequently employed. In designing non-inferiority trials, the trial should be well 
understood in advance and possible inconveniences should be taken into account. 
For these studies, the selection of the non-inferiority margin and the determination 
of the sample size are very important. 
 
 
 
 
Figure 1. Results of simulation for exact test 
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Figure 2. Results of simulation for Z test 
 
 
 
 
 
Figure 3. Results of simulation for Z test with continuity correction 
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In this study, the appropriate sample sizes for one proportion in non-
inferiority trials are calculated via three different test statistics. The results derived 
from all three test statistics were very close to one another. Therefore, it can be 
concluded that the non-inferiority odds ratio is directly influential on determining 
the proper sample size. In addition, in parallel to the findings of the previous 
literature, in our study the exaggeration of the non-inferiority odds ratio also leads 
to loss of power for the test. In this respect, this ratio should be determined with 
special care to ensure the appropriate sample size. 
Studies involving the comparison of effectiveness of two groups are common 
in medicine and veterinary. In this study, taking into accounts odds ratio which is 
the most frequently applied method to compare the effectiveness of two, the 
appropriate sample sizes for non-inferiority trials are calculated at 80% power and 
0.05 significance levels. The calculated values are given in practical tables to make 
it easier for the researchers those intend to employ the method. In addition, the 
accuracy of the results will definitely be higher in the studies that are to be 
conducted with proper sample sizes determined according to tables provided in this 
study. 
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Appendix A. Tables 
Table 1. Results of power analysis of one proportion non-inferiority for exact test 
 
Power N 
Non-Inf 
OR 
Actual 
OR 
Baseline 
prop. 
(PB) 
Target 
alpha 
Actual 
alpha Beta 
0.2399 50 0.7500 1.0000 0.5000 0.0500 0.0421 0.7601 
0.3822 100 0.7500 1.0000 0.5000 0.0500 0.0410 0.6178 
0.5325 150 0.7500 1.0000 0.5000 0.0500 0.4675 0.4675 
0.6381 200 0.7500 1.0000 0.5000 0.0500 0.0466 0.3619 
0.7153 250 0.7500 1.0000 0.5000 0.0500 0.0443 0.2847 
0.7735 300 0.7500 1.0000 0.5000 0.0500 0.0412 0.2265 
0.8044 306 0.7500 1.0000 0.5000 0.0500 0.0490 0.1956 
0.8451 350 0.7500 1.0000 0.5000 0.0500 0.0474 0.1549 
0.8749 400 0.7500 1.0000 0.5000 0.0500 0.0426 0.1251 
0.9142 450 0.7500 1.0000 0.5000 0.0500 0.0468 0.0858 
0.9300 500 0.7500 1.0000 0.5000 0.0500 0.0416 0.0700 
0.1611 50 0.8000 1.0000 0.5000 0.0500 0.0374 0.8389 
0.2421 100 0.8000 1.0000 0.5000 0.0500 0.0346 0.7579 
0.3416 150 0.8000 1.0000 0.5000 0.0500 0.0379 0.6584 
0.4718 200 0.8000 1.0000 0.5000 0.0500 0.0496 0.5282 
0.5252 250 0.8000 1.0000 0.5000 0.0500 0.0445 0.4748 
0.5687 300 0.8000 1.0000 0.5000 0.0500 0.0393 0.4313 
0.6458 350 0.8000 1.0000 0.5000 0.0500 0.0434 0.3542 
0.7088 400 0.8000 1.0000 0.5000 0.0500 0.0465 0.2912 
0.7602 450 0.8000 1.0000 0.5000 0.0500 0.0487 0.2398 
0.7922 489 0.8000 1.0000 0.5000 0.0500 0.0494 0.2078 
0.7764 500 0.8000 1.0000 0.5000 0.0500 0.0416 0.2236 
0.1013 50 0.8500 1.0000 0.5000 0.0500 0.0321 0.8987 
0.1841 100 0.8500 1.0000 0.5000 0.0500 0.0433 0.8159 
0.2313 150 0.8500 1.0000 0.5000 0.0500 0.0417 0.7687 
0.3104 200 0.8500 1.0000 0.5000 0.0500 0.0500 0.6896 
0.3290 250 0.8500 1.0000 0.5000 0.0500 0.0420 0.6710 
0.3864 300 0.8500 1.0000 0.5000 0.0500 0.0449 0.6136 
0.4363 350 0.8500 1.0000 0.5000 0.0500 0.0464 0.5637 
0.4801 400 0.8500 1.0000 0.5000 0.0500 0.0469 0.5199 
0.5188 450 0.8500 1.0000 0.5000 0.0500 0.0468 0.4812 
0.5534 500 0.8500 1.0000 0.5000 0.0500 0.0462 0.4466 
0.1013 50 0.9000 1.0000 0.5000 0.0500 0.0497 0.8987 
0.0967 100 0.9000 1.0000 0.5000 0.0500 0.0338 0.9033 
0.1442 150 0.9000 1.0000 0.5000 0.0500 0.0439 0.8558 
0.1790 200 0.9000 1.0000 0.5000 0.0500 0.0480 0.8210 
0.2055 250 0.9000 1.0000 0.5000 0.0500 0.0489 0.7945 
0.2265 300 0.9000 1.0000 0.5000 0.0500 0.0481 0.7735 
0.2436 350 0.9000 1.0000 0.5000 0.0500 0.0464 0.7564 
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Table 1 (continued). 
 
Power N 
Non-Inf 
OR 
Actual 
OR PB 
Target 
alpha 
Actual 
alpha Beta 
0.2579 400 0.9000 1.0000 0.5000 0.0500 0.0442 0.7421 
0.2700 450 0.9000 1.0000 0.5000 0.0500 0.0418 0.7300 
0.3114 500 0.9000 1.0000 0.5000 0.0500 0.0474 0.6886 
0.0595 50 0.9500 1.0000 0.5000 0.0500 0.0408 0.9405 
0.0666 100 0.9500 1.0000 0.5000 0.0500 0.0394 0.9334 
0.0825 150 0.9500 1.0000 0.5000 0.0500 0.0443 0.9175 
0.0895 200 0.9500 1.0000 0.5000 0.0500 0.0439 0.9105 
0.0920 250 0.9500 1.0000 0.5000 0.0500 0.0414 0.9080 
0.1126 300 0.9500 1.0000 0.5000 0.0500 0.0488 0.8874 
0.1094 350 0.9500 1.0000 0.5000 0.0500 0.0437 0.8906 
0.1251 400 0.9500 1.0000 0.5000 0.0500 0.0481 0.8749 
0.1193 450 0.9500 1.0000 0.5000 0.0500 0.0425 0.8807 
0.1318 500 0.9500 1.0000 0.5000 0.0500 0.0453 0.8682 
0.0325 50 0.9900 1.0000 0.5000 0.0500 0.0300 0.9675 
0.0443 100 0.9900 1.0000 0.5000 0.0500 0.0398 0.9557 
0.0430 150 0.9900 1.0000 0.5000 0.0500 0.0377 0.9570 
0.0518 200 0.9900 1.0000 0.5000 0.0500 0.0447 0.9482 
0.0568 250 0.9900 1.0000 0.5000 0.0500 0.0483 0.9432 
0.0594 300 0.9900 1.0000 0.5000 0.0500 0.0498 0.9406 
0.0487 350 0.9900 1.0000 0.5000 0.0500 0.0399 0.9513 
0.0605 400 0.9900 1.0000 0.5000 0.0500 0.0494 0.9395 
0.0598 450 0.9900 1.0000 0.5000 0.0500 0.0482 0.9402 
0.0587 500 0.9900 1.0000 0.5000 0.0500 0.0467 0.9413 
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Table 2. Results of power analysis of one proportion non-inferiority for Z test 
 
Power N 
Non-Inf 
OR 
Actual 
OR PB 
Target 
alpha 
Actual 
alpha Beta 
0.2399 50 0.7500 1.0000 0.5000 0.0500 0.0421 0.7601 
0.4602 100 0.7500 1.0000 0.5000 0.0500 0.0618 0.5398 
0.5325 150 0.7500 1.0000 0.5000 0.0500 0.0465 0.4675 
0.6381 200 0.7500 1.0000 0.5000 0.0500 0.0466 0.3619 
0.7153 250 0.7500 1.0000 0.5000 0.0500 0.0443 0.2847 
0.8091 294 0.7500 1.0000 0.5000 0.0500 0.0562 0.1909 
0.8067 300 0.7500 1.0000 0.5000 0.0500 0.0525 0.1933 
0.8451 350 0.7500 1.0000 0.5000 0.0500 0.0474 0.1549 
0.8944 400 0.7500 1.0000 0.5000 0.0500 0.0526 0.1056 
0.9142 450 0.7500 1.0000 0.5000 0.0500 0.0468 0.0858 
0.9413 500 0.7500 1.0000 0.5000 0.0500 0.0502 0.0587 
0.1611 50 0.8000 1.0000 0.5000 0.0500 0.0374 0.8389 
0.3086 100 0.8000 1.0000 0.5000 0.0500 0.0529 0.6914 
0.4033 150 0.8000 1.0000 0.5000 0.0500 0.0534 0.5967 
0.4718 200 0.8000 1.0000 0.5000 0.0500 0.0496 0.5282 
0.5252 250 0.8000 1.0000 0.5000 0.0500 0.0445 0.4748 
0.6136 300 0.8000 1.0000 0.5000 0.0500 0.0502 0.3864 
0.6847 350 0.8000 1.0000 0.5000 0.0500 0.0542 0.3153 
0.7088 400 0.8000 1.0000 0.5000 0.0500 0.0465 0.7088 
0.7602 450 0.8000 1.0000 0.5000 0.0500 0.0487 0.2398 
0.8051 488 0.8000 1.0000 0.5000 0.0500 0.0546 0.1949 
0.8022 500 0.8000 1.0000 0.5000 0.0500 0.0502 0.1978 
0.1611 50 0.8500 1.0000 0.5000 0.0500 0.0586 0.8389 
0.1841 100 0.8500 1.0000 0.5000 0.0500 0.0433 0.8159 
0.2839 150 0.8500 1.0000 0.5000 0.0500 0.0585 0.7161 
0.3104 200 0.8500 1.0000 0.5000 0.0500 0.0500 0.6896 
0.3760 250 0.8500 1.0000 0.5000 0.0500 0.0546 0.6240 
0.3864 300 0.8500 1.0000 0.5000 0.0500 0.0449 0.6136 
0.4363 350 0.8500 1.0000 0.5000 0.0500 0.0464 0.5637 
0.4801 400 0.8500 1.0000 0.5000 0.0500 0.0469 0.5199 
0.5188 450 0.8500 1.0000 0.5000 0.0500 0.0468 0.4812 
0.5534 500 0.8500 1.0000 0.5000 0.0500 0.0462 0.4466 
0.1013 50 0.9000 1.0000 0.5000 0.0500 0.0497 0.8987 
0.1356 100 0.9000 1.0000 0.5000 0.0500 0.0518 0.8644 
0.1442 150 0.9000 1.0000 0.5000 0.0500 0.0439 0.8558 
0.1790 200 0.9000 1.0000 0.5000 0.0500 0.0480 0.8210 
0.2055 250 0.9000 1.0000 0.5000 0.0500 0.0489 0.7945 
0.2265 300 0.9000 1.0000 0.5000 0.0500 0.0481 0.7735 
0.2436 350 0.9000 1.0000 0.5000 0.0500 0.0464 0.7564 
0.2912 400 0.9000 1.0000 0.5000 0.0500 0.0544 0.7088 
0.3021 450 0.9000 1.0000 0.5000 0.0500 0.0509 0.6979 
0.3114 500 0.9000 1.0000 0.5000 0.0500 0.0474 0.6886 
0.0595 50 0.9500 1.0000 0.5000 0.0500 0.0408 0.9405 
0.0967 100 0.9500 1.0000 0.5000 0.0500 0.0597 0.9033 
GÜLLÜ & TEKINDAL 
15 
Table 2 (continued). 
 
Power N 
Non-Inf 
OR 
Actual 
OR PB 
Target 
alpha 
Actual 
alpha Beta 
0.0825 150 0.9500 1.0000 0.5000 0.0500 0.0443 0.9175 
0.0895 200 0.9500 1.0000 0.5000 0.0500 0.0439 0.9105 
0.1147 250 0.9500 1.0000 0.5000 0.0500 0.0540 0.8853 
0.1126 300 0.9500 1.0000 0.5000 0.0500 0.0488 0.8874 
0.1308 350 0.9500 1.0000 0.5000 0.0500 0.0545 0.8692 
0.1251 400 0.9500 1.0000 0.5000 0.0500 0.0481 0.8749 
0.1391 450 0.9500 1.0000 0.5000 0.0500 0.0517 0.8609 
0.1518 500 0.9500 1.0000 0.5000 0.0500 0.0545 0.8482 
0.0595 50 0.9900 1.0000 0.5000 0.0500 0.0554 0.9405 
0.0666 100 0.9900 1.0000 0.5000 0.0500 0.0603 0.9334 
0.0603 150 0.9900 1.0000 0.5000 0.0500 0.0533 0.9397 
0.0518 200 0.9900 1.0000 0.5000 0.0500 0.0447 0.9482 
0.0568 250 0.9900 1.0000 0.5000 0.0500 0.0483 0.9432 
0.0594 300 0.9900 1.0000 0.5000 0.0500 0.0498 0.9406 
0.0605 350 0.9900 1.0000 0.5000 0.0500 0.0500 0.9395 
0.0605 400 0.9900 1.0000 0.5000 0.0500 0.0494 0.9395 
0.0598 450 0.9900 1.0000 0.5000 0.0500 0.0482 0.9402 
0.0587 500 0.9900 1.0000 0.5000 0.0500 0.0467 0.9413 
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Table 3. Results of power analysis of one proportion non-inferiority for Z test with 
continuity correction 
 
Power N 
Non-Inf 
OR 
Actual 
OR PB 
Target 
alpha 
Actual 
alpha Beta 
0.2399 50 0.7500 1.0000 0.5000 0.0500 0.0421 0.7601 
0.3822 100 0.7500 1.0000 0.5000 0.0500 0.0410 0.6178 
0.5325 150 0.7500 1.0000 0.5000 0.0500 0.0465 0.4675 
0.6381 200 0.7500 1.0000 0.5000 0.0500 0.0466 0.3619 
0.7153 250 0.7500 1.0000 0.5000 0.0500 0.0443 0.2847 
0.8083 296 0.7500 1.0000 0.5000 0.0500 0.0549 0.1917 
0.8067 300 0.7500 1.0000 0.5000 0.0500 0.0525 0.1933 
0.8451 350 0.7500 1.0000 0.5000 0.0500 0.0474 0.1549 
0.8944 400 0.7500 1.0000 0.5000 0.0500 0.0526 0.1056 
0.9142 450 0.7500 1.0000 0.5000 0.0500 0.0468 0.0858 
0.9413 500 0.7500 1.0000 0.5000 0.0500 0.0502 0.0587 
0.2399 50 0.8000 1.0000 0.5000 0.0500 0.0670 0.7601 
0.3086 100 0.8000 1.0000 0.5000 0.0500 0.0529 0.6914 
0.4033 150 0.8000 1.0000 0.5000 0.0500 0.0534 0.5967 
0.4718 200 0.8000 1.0000 0.5000 0.0500 0.0496 0.5282 
0.5252 250 0.8000 1.0000 0.5000 0.0500 0.0445 0.4748 
0.6136 300 0.8000 1.0000 0.5000 0.0500 0.0502 0.3864 
0.6847 350 0.8000 1.0000 0.5000 0.0500 0.0542 0.3153 
0.7088 400 0.8000 1.0000 0.5000 0.0500 0.0465 0.2912 
0.7602 450 0.8000 1.0000 0.5000 0.0500 0.0487 0.2398 
0.8046 490 0.8000 1.0000 0.5000 0.0500 0.0538 0.1954 
0.8022 500 0.8000 1.0000 0.5000 0.0500 0.0502 0.1978 
0.1611 50 0.8500 1.0000 0.5000 0.0500 0.0586 0.8389 
0.1841 100 0.8500 1.0000 0.5000 0.0500 0.0433 0.8159 
0.2839 150 0.8500 1.0000 0.5000 0.0500 0.0585 0.7161 
0.3104 200 0.8500 1.0000 0.5000 0.0500 0.0500 0.6896 
0.3760 250 0.8500 1.0000 0.5000 0.0500 0.0546 0.6240 
0.3864 300 0.8500 1.0000 0.5000 0.0500 0.0449 0.6136 
0.4363 350 0.8500 1.0000 0.5000 0.0500 0.0464 0.5637 
0.4801 400 0.8500 1.0000 0.5000 0.0500 0.0469 0.5199 
0.5188 450 0.8500 1.0000 0.5000 0.0500 0.0468 0.4812 
0.5534 500 0.8500 1.0000 0.5000 0.0500 0.0462 0.4466 
0.1013 50 0.9000 1.0000 0.5000 0.0500 0.0497 0.8987 
0.1356 100 0.9000 1.0000 0.5000 0.0500 0.0518 0.8644 
0.1442 150 0.9000 1.0000 0.5000 0.0500 0.0439 0.8558 
0.1790 200 0.9000 1.0000 0.5000 0.0500 0.0480 0.8210 
0.2055 250 0.9000 1.0000 0.5000 0.0500 0.0489 0.7945 
0.2265 300 0.9000 1.0000 0.5000 0.0500 0.0481 0.7735 
0.2436 350 0.9000 1.0000 0.5000 0.0500 0.0464 0.7564 
0.2912 400 0.9000 1.0000 0.5000 0.0500 0.0544 0.7088 
0.3021 450 0.9000 1.0000 0.5000 0.0500 0.0509 0.6979 
0.3114 500 0.9000 1.0000 0.5000 0.0500 0.0474 0.6886 
0.0595 50 0.9500 1.0000 0.5000 0.0500 0.0408 0.9405 
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Table 3 (continued). 
 
Power N 
Non-Inf 
OR 
Actual 
OR PB 
Target 
alpha 
Actual 
alpha Beta 
0.0967 100 0.9500 1.0000 0.5000 0.0500 0.0597 0.9033 
0.0825 150 0.9500 1.0000 0.5000 0.0500 0.0443 0.9175 
0.0895 200 0.9500 1.0000 0.5000 0.0500 0.0439 0.9105 
0.1147 250 0.9500 1.0000 0.5000 0.0500 0.0540 0.8853 
0.1126 300 0.9500 1.0000 0.5000 0.0500 0.0488 0.8874 
0.1308 350 0.9500 1.0000 0.5000 0.0500 0.0545 0.8692 
0.1251 400 0.9500 1.0000 0.5000 0.0500 0.0481 0.8749 
0.1391 450 0.9500 1.0000 0.5000 0.0500 0.0517 0.8609 
0.1518 500 0.9500 1.0000 0.5000 0.0500 0.0545 0.8482 
0.0595 50 0.9900 1.0000 0.5000 0.0500 0.0554 0.9405 
0.0666 100 0.9900 1.0000 0.5000 0.0500 0.0603 0.9334 
0.0603 150 0.9900 1.0000 0.5000 0.0500 0.0533 0.9397 
0.0518 200 0.9900 1.0000 0.5000 0.0500 0.0447 0.9482 
0.0568 250 0.9900 1.0000 0.5000 0.0500 0.0483 0.9432 
0.0594 300 0.9900 1.0000 0.5000 0.0500 0.0498 0.9406 
0.0605 350 0.9900 1.0000 0.5000 0.0500 0.0500 0.9395 
0.0605 400 0.9900 1.0000 0.5000 0.0500 0.0494 0.9395 
0.0598 450 0.9900 1.0000 0.5000 0.0500 0.0482 0.9402 
0.0587 500 0.9900 1.0000 0.5000 0.0500 0.0467 0.9413 
 
